Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies
Journal of Immunotherapy and Precision Oncology · 16.03.2026 · 9 (1) · 25-31
DOI: 10.36401/jipo-25-34 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 16.03.2026. Verfasst von Umut Dişel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Acibadem Adana Hospital, Adana, Turkey. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
High-grade gliomas are associated with dismal outcomes and have devastating neurologic sequelae. Standard-of-care surgery, radiation, and temozolomide yield a median survival of 14–16 months in patients with glioblastoma (GBM).
Methods
We report four patients with high-grade glioma (two with GBM; one initially diagnosed with GBM, now classified as World Health Organization grade 4 IDH1- mutant astrocytoma; and one with oligosarcoma [grade 4]). Tumor next-generation sequencing (NGS) was performed for all four patients, and they were treated based on their biomarkers.
Results
NGS yielded actionable alterations targeted after conventional surgery/chemoradiation therapy: imatinib (for KIT and PDGRA amplification) and bevacizumab (for KDR [ VEGFR2 ] amplification); everolimus (mTOR inhibitor for TSC2 and PTEN loss-of-function alterations); and ivosidenib (IDH1 inhibitor for IDH1 mutations in two cases, including the oligosarcoma). Three patients remain in radiographic and clinical remission at 39+, 48, and 52+ months; the patient with oligosarcoma showed clinical and imaging response lasting 8 months.
Conclusions
Our exceptional responders with high-grade gliomas suggest that biomarker-matched targeted therapy can benefit select patients with high-grade glioma and warrants prospective clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Acibadem Adana Hospital, Adana, Turkey.
- Center for Personalized Cancer Therapy, Moores Cancer Center, UCSD, San Diego, CA, USA.
- City of Hope, Duarte, CA, USA.
- Department of Pathology Acibadem Altunizade Hospital, Istanbul, Turkey.
- Division of Neuro-Oncology, Miami Cancer Institute, Baptist Health South Florida, FL, USA.
- Clinical Cancer Center - Froedtert Hospital, Medical College of Wisconsin, Milwaukee, WI, USA.
ORCID-Profile: Umut Dişel
Zitieren
APA
Dişel, U., Kato, S., Shreenivas, A., Danyeli, A. E., Ahluwalia, M. S., & Kurzrock, R. (2026). Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. Journal of Immunotherapy and Precision Oncology, 9(1), 25-31. https://doi.org/10.36401/jipo-25-34
Vancouver
Dişel U, Kato S, Shreenivas A, Danyeli AE, Ahluwalia MS, Kurzrock R. Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies. Journal of Immunotherapy and Precision Oncology. 2026;9(1):25-31. doi:10.36401/jipo-25-34
BibTeX
@article{Diel2026,
author = {Dişel, Umut and Kato, Shumei and Shreenivas, Aditya and Danyeli, Ayca Ersen and Ahluwalia, Manmeet S and Kurzrock, Razelle},
title = {Lessons from Exceptional Responders with High-Grade Brain Tumors Treated with Precision Targeted Therapies},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2026},
volume = {9},
number = {1},
pages = {25--31},
doi = {10.36401/jipo-25-34}
}
EUVIMED